#United States #San Diego #Class Action #Securities Fraud #Rocket Pharmaceuticals

Rocket Pharmaceuticals Faces Class Action Lawsuit

Overview of the Situation

On July 16, 2025, Robbins Geller Rudman & Dowd LLP announced that purchasers of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) shares between February 27, 2025, and May 26, 2025, may have the opportunity to be appointed as lead plaintiff in a class action lawsuit. This lawsuit has been initiated due to serious allegations of misleading statements made by Rocket Pharmaceuticals regarding their clinical trials and the substantial financial losses that many investors have incurred as a result.

The Allegations

The lawsuit, referenced as Ho v. Rocket Pharmaceuticals, Inc., primarily claims that Rocket Pharmaceuticals, along with one of its top executives, violated the Securities Exchange Act of 1934. The core of the allegations centers on the company's Phase 2 clinical trial for RP-A501, which is aimed at treating Danon disease. Despite revealing certain aspects of this pivotal trial to investors, the defendants also allegedly concealed crucial information regarding serious adverse events associated with the treatment, including participant deaths linked to the trial.

One of the critical points raised in the lawsuit is the amendment of the trial protocol without adequate disclosure to investors. The trial protocol was altered to include a new immunomodulatory treatment without informing shareholders, raising concerns about transparency and accountability. Furthermore, on May 27, 2025, it was publicly disclosed that the U.S. Food and Drug Administration had imposed a clinical hold on the study following reports of serious adverse events, including the death of a trial participant.

This news led to a significant decline in Rocket Pharmaceuticals' stock price, adding to the financial burden on investors who relied on the company’s representations regarding the safety and integrity of the clinical trial.

The Lead Plaintiff Process

The Private Securities Litigation Reform Act of 1995 allows any investor who acquired Rocket Pharmaceuticals securities during the specified class period to apply for the role of lead plaintiff in this lawsuit. A lead plaintiff typically has the most substantial financial interest in the case and is also able to adequately represent the interests of the entire class. Notably, serving as a lead plaintiff does not restrict an investor's right to partake in any potential recovery from the lawsuit.

About Robbins Geller Rudman & Dowd LLP

Robbins Geller is recognized as one of the world's foremost law firms specializing in representing investors in securities fraud and shareholder litigation. The firm has established a significant reputation for securing monetary relief for investors, having recovered over $2.5 billion in securities-related class action cases in 2024 alone. Their successes include some of the largest securities class action recoveries in history.

Conclusion

Investors who have suffered substantial losses in Rocket Pharmaceuticals may have a crucial opportunity on their hands. By becoming involved in the class action lawsuit, they can seek justice while potentially recovering some of their lost capital. The deadline for interested investors to seek lead plaintiff status is Monday, August 11, 2025. Those affected can provide their information through Robbins Geller's specified channels to begin the process.

For more details and to join the class action, interested investors can visit their website or contact the law firm directly. As the legal proceedings unfold, it is essential for investors to stay informed and prepared for the potential outcomes of this significant legal battle.